Are highly active and aggressive multiple sclerosis the same entity?

Are highly active and aggressive multiple sclerosis the same entity?

Detalhes bibliográficos
Principais autores:	Jorge Correale, Carolina A. Rush, Andrés Barboza
Formato:	Artigo
Idioma:	English
Publicado em:	Frontiers Media S.A. 2023-03-01
coleção:	Frontiers in Neurology
Assuntos:	multiple sclerosis aggressive multiple sclerosis highly active multiple sclerosis treatment of highly active MS treatment of aggressive MS
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1132170/full

Registros relacionados

Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia
por: A. N. Boiko, et al.
Publicado em: (2022-08-01)

The relationship between interpersonal sensitivity and relational aggression with the mediating role of resilience in married people with multiple sclerosis
por: Seyedeh Shaghayegh Ahmadi, et al.
Publicado em: (2024-03-01)

Monitoring response to disease-modifying treatment in multiple sclerosis
por: J. Río, et al.
Publicado em: (2023-04-01)

Multiple sclerosis : recovery of function and neurorehabilitation /
por: Kesselring, Jurg, et al.
Publicado em: (c201)

Multiple sclerosis /
por: 546326 Dobson, Ruth, et al.
Publicado em: (2013)

Effects of the ketogenic diet on multiple sclerosis with a focus on the paediatric population
por: Patrycja Szponarowicz, et al.
Publicado em: (2023-05-01)

Optimization of therapy in secondary progressive multiple sclerosis
por: A. N. Boyko, et al.
Publicado em: (2024-08-01)

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets
por: N. A. Totolyan, et al.
Publicado em: (2020-10-01)

The role of lifestyle physical activity in preventing multiple sclerosis
por: Józef Opara
Publicado em: (2024-09-01)

Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice
por: S. V. Petrov, et al.
Publicado em: (2022-02-01)

Beyond the division of multiple sclerosis into different subgroups: The Concept of Connectomopathy
por: Abdorreza Naser Moghadasi, et al.
Publicado em: (2024-05-01)

The Effectiveness of Mindfulness-based Stress Reduction on Sleep Quality in Patients With Multiple Sclerosis
por: Fatemeh Zargar, et al.
Publicado em: (2024-07-01)

Uveitis Related with Multiple Sclerosis
por: Sirel Gür Güngör, et al.
Publicado em: (2012-12-01)

A review of treatment of relapsing-remitting type of multiple sclerosis (RRMS)
por: Arkadiusz Bydliński, et al.
Publicado em: (2024-05-01)

Multiple Sclerosis: Methods of Treatment and Rehabilitation
por: Yuriy Lysenko
Publicado em: (2017-06-01)

Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis
por: A. N. Boyko, et al.
Publicado em: (2019-12-01)

It's not all in your head : anxiety, depression, mood swings, and multiple sclerosis /
por: Farrell, Patricia, 1940-
Publicado em: ([201)

Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis
por: K. Z. Bakhtiyarova, et al.
Publicado em: (2020-06-01)

Spinal Cord Analysis in People with Multiple Sclerosis
por: Fatemeh Ebrahimi Meymand, et al.
Publicado em: (2018-04-01)

The Long Road of Immunotherapeutics against Multiple Sclerosis
por: Vasso Apostolopoulos, et al.
Publicado em: (2020-05-01)

بررسی میزان شیوع هیپوتیروئیدی در افراد مبتلا به Multiple Sclerosis‏ ‏مراجعه کننده به بیمارستان الزهرای (س) اصفهان در سال 1392
por: Masoud Etemadifar, et al.
Publicado em: (2016-08-01)

Clinical and epidemiological features of patients with multiple sclerosis in the Kursk Region
por: V. B. Laskov, et al.
Publicado em: (2017-03-01)

Impact of aging on treatment considerations for multiple sclerosis patients
por: Gabrielle Macaron, et al.
Publicado em: (2023-07-01)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
por: Francisco Gascón-Giménez, et al.
Publicado em: (2023-03-01)

Correlation Between the Scores of Common Balance Tests for Patients With Multiple Sclerosis
por: Amir Moghaddam, et al.
Publicado em: (2023-07-01)

Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis
por: Enric Monreal, et al.
Publicado em: (2024-04-01)

Multiple Sclerosis in a Multi-Ethnic Population in Houston, Texas: A Retrospective Analysis
por: Vicki Mercado, et al.
Publicado em: (2020-11-01)

Association of Relapse of Multiple Sclerosis with Increased Serum Levels of Leptin and Decreased Aerobic Capacity in Women
por: Motahareh Mokhtarzadeh, et al.
Publicado em: (2017-01-01)

Investigating the Profile of Multiple Sclerosis Registry Among Iranian Children: Background, Aims, Design, and Preliminary Results
por: Ali Nikkhah, et al.
Publicado em: (2024-04-01)

Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice
por: S. V. Petrov, et al.
Publicado em: (2020-08-01)

Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a)
por: A. N. Boyko
Publicado em: (2022-08-01)

Treatment Management of Patients with Multiple Sclerosis and Nursing Approaches
por: Öznur Erbay, et al.
Publicado em: (2020-01-01)

Clinical markers for unfavorable course of multiple sclerosis
por: Mariya S. Matrosova, et al.
Publicado em: (2023-09-01)

Escalation or high-efficacy disease-modifying therapies in multiple sclerosis
por: Elnaz Asadollahzadeh
Publicado em: (2023-07-01)

Head and Brain Size in Pediatric Multiple Sclerosis
por: J Gordon Millichap
Publicado em: (2012-02-01)

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021
por: Crystal Watson, et al.
Publicado em: (2023-09-01)

Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis
por: F. A. Khabirov, et al.
Publicado em: (2024-08-01)

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
por: A. N. Boyko, et al.
Publicado em: (2019-11-01)

From genes to function: the next challenge to understanding multiple sclerosis
por: Fugger, L, et al.
Publicado em: (2009)

Normal-appearing white and grey matter damage in multiple sclerosis /
por: Filippi, M., et al.
Publicado em: (2004)